S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
15 A.I. Trading Opportunities a Day (Ad)
10 Ways Entrepreneurs Can Navigate a Down Economy
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
15 A.I. Trading Opportunities a Day (Ad)
PwC Australia sidelines 9 directors as leak of tax information investigated
South African president appoints judge to oversee weapons-for-Russia inquiry
15 A.I. Trading Opportunities a Day (Ad)
Drought-struck Barcelona quenches thirst with costly desalination
Poland imposes sanctions on 365 Belarusians over 'draconian' verdict against journalist
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
15 A.I. Trading Opportunities a Day (Ad)
10 Ways Entrepreneurs Can Navigate a Down Economy
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
15 A.I. Trading Opportunities a Day (Ad)
PwC Australia sidelines 9 directors as leak of tax information investigated
South African president appoints judge to oversee weapons-for-Russia inquiry
15 A.I. Trading Opportunities a Day (Ad)
Drought-struck Barcelona quenches thirst with costly desalination
Poland imposes sanctions on 365 Belarusians over 'draconian' verdict against journalist
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
15 A.I. Trading Opportunities a Day (Ad)
10 Ways Entrepreneurs Can Navigate a Down Economy
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
15 A.I. Trading Opportunities a Day (Ad)
PwC Australia sidelines 9 directors as leak of tax information investigated
South African president appoints judge to oversee weapons-for-Russia inquiry
15 A.I. Trading Opportunities a Day (Ad)
Drought-struck Barcelona quenches thirst with costly desalination
Poland imposes sanctions on 365 Belarusians over 'draconian' verdict against journalist
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
15 A.I. Trading Opportunities a Day (Ad)
10 Ways Entrepreneurs Can Navigate a Down Economy
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
15 A.I. Trading Opportunities a Day (Ad)
PwC Australia sidelines 9 directors as leak of tax information investigated
South African president appoints judge to oversee weapons-for-Russia inquiry
15 A.I. Trading Opportunities a Day (Ad)
Drought-struck Barcelona quenches thirst with costly desalination
Poland imposes sanctions on 365 Belarusians over 'draconian' verdict against journalist
TSE:I

Intellipharmaceutics International (I) Stock Forecast, Price & News

C$3.23
+0.04 (+1.25%)
(As of 03/17/2017)
Compare
Today's Range
C$3.15
C$3.26
50-Day Range
C$3.23
C$3.23
52-Week Range
C$1.78
C$4.50
Volume
7,625 shs
Average Volume
16,872 shs
Market Capitalization
C$97.40 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

About Intellipharmaceutics International

Intellipharmaceutics International Inc is a Canada-based pharmaceutical company engaged in the research, development and manufacture of controlled-release and targeted-release oral solid dosage drugs. Its Hypermatrix technology is a multidimensional controlled-release drug delivery platform that is applied to the development of a range of existing and new pharmaceuticals. Based on this technology platform, it has developed various drug delivery systems and a pipeline of products, and product candidates in various stages of development, in therapeutic areas that include neurology and cardiovascular. Its pipeline of products includes Rexista Oxycodone, Regabatin XR, Generic Focalin XR, Generic Effexor XR, Generic Protonix, Generic Glucophage XR, Generic Seroquel XR, Generic Lamictal XR, Generic Keppra XR, Generic Pristiq and Generic Ranexa. Its generic product candidates also include Trazodone hydrochloride extended-release tablets and Carvedilol phosphate extended-release capsules.

Receive I Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Intellipharmaceutics International and its competitors with MarketBeat's FREE daily newsletter.

I Stock News Headlines

Intellipharmaceutics International Inc. (I4AA.F)
BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
Intellipharmaceutics International Inc. (IPCIF)
Free SMS Trade Alerts. Up to 15 opportunities a day.
Using our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.
Intellipharmaceutics International Inc
Stocks in play: Intellipharmaceutics International Inc.
Intellipharmaceutics Announces Third Quarter 2021 Results
North American Morning Briefing: Investors to -2-
See More Headlines
Receive I Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Intellipharmaceutics International and its competitors with MarketBeat's FREE daily newsletter.

I Company Calendar

Today
5/29/2023
Next Earnings (Estimated)
6/01/2023

Industry, Sector and Symbol

Industry
Wireless Telecommunications
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
1,195
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Market Cap
C$97.40 million
Optionable
Optionable
Beta
N/A

Key Executives

  • Isa Odidi Ph.D.
    Chairman of the Board, Chief Executive Officer
  • Amina Odidi Ph.D.
    President, Chief Operating Officer, Director
  • Andrew Patient
    Chief Financial Officer
  • John N. Allport
    Vice President - Legal Affairs and Licensing, Secretary, Director
  • Patrick N. Yat Ph.D.
    Vice President - Pharmaceutical Analysis and Chemistry
  • Kenneth Keirstead
    Independent Director
  • Bahadur Madhani
    Independent Director
  • Eldon R. Smith M.D. (Age 75)
    Independent Director













I Stock - Frequently Asked Questions

How have I shares performed in 2023?

Intellipharmaceutics International's stock was trading at C$3.23 on January 1st, 2023. Since then, I shares have increased by 0.0% and is now trading at C$3.23.
View the best growth stocks for 2023 here
.

When is Intellipharmaceutics International's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, June 1st 2023.
View our I earnings forecast
.

What other stocks do shareholders of Intellipharmaceutics International own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Intellipharmaceutics International investors own include QuickLogic (QUIK), VBI Vaccines (VBIV), NeuLion (NLN), Micron Technology (MU), Mallinckrodt (MNK), Intellipharmaceutics International (IPCIF), Fitbit (FIT), Clean Commodities (CLE), Calithera Biosciences (CALA) and BlackBerry (BB).

What is Intellipharmaceutics International's stock symbol?

Intellipharmaceutics International trades on the Toronto Stock Exchange (TSX) under the ticker symbol "I."

How do I buy shares of Intellipharmaceutics International?

Shares of I stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What is Intellipharmaceutics International's stock price today?

One share of I stock can currently be purchased for approximately C$3.23.

How much money does Intellipharmaceutics International make?

Intellipharmaceutics International (TSE:I) has a market capitalization of C$97.40 million.

How many employees does Intellipharmaceutics International have?

The company employs 1,195 workers across the globe.

How can I contact Intellipharmaceutics International?

Intellipharmaceutics International's mailing address is 30 Worcester Rd, ETOBICOKE, ON M9W 5X2, Canada. The official website for the company is www.intelsat.com. The company can be reached via phone at +1-416-7983001.

This page (TSE:I) was last updated on 5/29/2023 by MarketBeat.com Staff

My Account -